Skip to main content

Table 1 Pharmacokinetic parameters of ABR, ABR-NP, and Apt-ABR-NP in Swiss Albino mice following intraperitoneal administration (0.4 mg/kg)

From: ΔPSap4#5 surface-functionalized abiraterone-loaded nanoparticle successfully inhibits carcinogen-induced prostate cancer in mice: a mechanistic investigation

Parameters

ABR

ABR-NP

Apt-ABR-NP

Cmax (ng/ml)

25 ± 2.5

30 ± 2.5*

32 ± 2.4*

Tmax (h)

2.0 ± 0.2

9.0 ± 0.4*

9.0 ± 0.5*

AUC last (ng h/ml)

547 ± 27

1204 ± 167*

1356 ± 175*

AUC 0–∞ (ng h/ml)

582 ± 30

1672 ± 175*

1975 ± 194*

AUMC (ng h2/ml)

12,345 ± 416

34,325 ± 544*

39,603 ± 622*

T1/2 (h)

12 ± 0.4

36 ± 1.7*

39 ± 2.2*

MRT (h)

22.5 ± 1.1

28.5 ± 1.6*

29.2 ± 1.2*

Vd (ml)

316 ± 10

430 ± 12*

415 ± 20*

Clearance (ml/h)

18.2 ± 0.9

8.3 ± 0.8*

7.4 ± 0.2*

  1. Data show mean ± SD (n = 3). Statistical analysis was carried out to one-way ANOVA analysis, and the p-value was calculated through Tukey’s post-test (p < 0.05) when compared against ABR control. Data shown by star (*) were significant compared to the ABR control group